Tridek-One

company

About

Tridek-One is a biopharmaceutical company aiming to develop immunomodulatory compounds targeting the CD31 pathway.

  • Évry,Ile-de-France,France
  • 1 - 10

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
€16M
Industries
Biotechnology,Health Care,Life Science
Founded date
Jan 1, 2018
Number Of Employee
1 - 10
Operating Status
Active

Tridek is a developer of immunomodulatory products intended for moderating overactive responses without blockade. The company's product is a peptide which maintains cluster of truncated CD31 to the membrane for a diversity of auto-immune and inflammatory disorders, enabling medical companies to treat their patients with better drugs and give them a better life.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
€19M
Tridek-One has raised a total of €19M in funding over 2 rounds. Their latest funding was raised on Sep 15, 2022 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 15, 2022 Series Unknown €16M 5 Pureos Bioventures Detail
Jun 4, 2019 Series Unknown €3M 2 AdBio partners Detail

Investors

Number of Lead Investors
Number of Investors
2
5
Tridek-One is funded by 5 investors. Pureos Bioventures and AdBio partners are the most recent investors.
Investor Name Lead Investor Funding Round
Pureos Bioventures Yes Series Unknown
AdBio partners Series Unknown
Advent Life Sciences Series Unknown
Bioqube Ventures Series Unknown
Bpifrance Series Unknown

Employee Profiles

Number of Employee Profiles
4
Tridek-One has 4 current employee profiles, including Board member Klaus Breiner
Board member
Board member
Board member